Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 4, 2012, Pages 977-983

  Wenisch, Judith M ^a   Meyer, Brigitte ^a   Fuhrmann, Valentin ^a   Saria, Katrin ^a   Zuba, Clara ^a   Dittrich, Peter ^b   Thalhammer, Florian ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Acute renal failure; Antimicrobial therapy; Renal replacement therapy

Indexed keywords

DAPTOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BLOOD SAMPLING; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PROTEIN BINDING;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-BACTERIAL AGENTS; AUSTRIA; BACTERIAL INFECTIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRITICAL ILLNESS; DAPTOMYCIN; FEMALE; GRAM-POSITIVE BACTERIA; HEMOFILTRATION; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PLASMA; TIME FACTORS;

EID: 84858681542     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr551     Document Type: Article

References (29)

1. Sauermann R, Rothenburger M, Graninger W et al. Daptomycin: a review 4 years after first approval. Pharmacology 2008; 81: 79-91.
2. Cotterill S. Antimicrobial prescribing in patients on haemofiltration. J Antimicrob Chemother 1995; 36: 773-80.
3. Vincent JL, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
4. Woodworth JR, Nyhart EH Jr, Brier GL et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 318-25.
5. Dvorchik BH, Brazier D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
6. Benvenuto M, Benziger DP, Yankelev S et al. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 3245-9.
7. Liang SH, Sheng WH, Huang YT et al. Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chemotherapy 2009; 55: 91-6.
8. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38: 994-1000.
9. Rybak MJ, Hershberger E, Moldovan T et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-6.
10. Vance-Bryan K, Larson TA, Rotschafer JC et al. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1992; 36: 2334-7.
11. Bhavnani SM, Rubino CM, Ambrose PG et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50: 1568-74.
12. Hanberger H, Nilsson LE, Maller R et al. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 1991; 35: 1710-6.
13. Vilay AM, Grio M, Depestel DD et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011; 39: 19-25.
14. Wagner CC, Steiner I, Zeitlinger M. Daptomycin elimination by CVVH in vitro: evaluation of factors influencing sieving and membrane adsorption. Int J Clin Pharmacol Ther 2009; 47: 178-86.
15. Cubicin Prescribing Information. 2010. http://www.cubicin.com/pdf/PrescribingInformation.pdf (21 December 2011, date last accessed).
16. Flandrois JP, Fardel G, Carret G. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob Agents Chemother 1988; 32: 454-7.
17. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007; 60: 334-40.
18. Leitner JM, Meyer B, Fuhrmann V et al. Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. J Antimicrob Chemother 2011; 66: 880-4.
19. Martens-Lobenhoffer J, Kielstein JT, Oye C et al. Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 875: 546-50.
20. Jaki T, Wolfsegger MJ. Estimation of pharmacokinetic parameters with the R package PK. Pharmaceutical Statistics 2011; 10: 284-8.
21. Meyer B, Ahmed el Gendy S, Delle Karth G et al. How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res 2003; 26: 135-40.
22. Meyer B, Traunmüller F, Hamwi A et al. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage. Int J Clin Pharmacol Ther 2004; 42: 556-60.
23. Louie A, Kaw P, Liu W et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001; 45: 845-51.
24. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
25. Tally FP, Zeckel M, Wasilewski MM et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs 1999; 8: 1223-38.
26. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-8.
27. Salama NN, Segal JH, Churchwell MD et al. Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol Dial Transplant 2010; 25: 1279-84.
28. Salama NN, Segal JH, Churchwell MD et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol 2009; 4: 1190-4.
29. Oleson FB Jr, Berman CL, Kirkpatrick JB et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44: 2948-53.